Abridge
Intelligence at the point of conversation
SaaS
📍 Pittsburgh, Pennsylvania
Founded 2018
Current Valuation
$5.7B
as of 2025-Q2
UNICORN
Abridge is an enterprise-grade AI platform that transforms clinical conversations into structured documentation and actionable insights. Founded by cardiologist Dr. Shiv Rao in 2018, the company uses generative AI and ambient listening to capture patient-clinician conversations and automatically generate clinical notes, reducing administrative burden and allowing clinicians to focus on patient care. The platform integrates with Epic EHR systems and supports 55 medical specialties across 28 languages, serving over 150 health systems including Kaiser Permanente, Mayo Clinic, Johns Hopkins, and UPMC.
Company Profile
HQ
Pittsburgh, Pennsylvania
Est. Revenue
$100M (2025-Q2)
Growth
900% YoY ARR growth; deployed to 150+ enterprise health systems; tracking 50M+ medical conversations annually
Last Round
Series E — $300M (Jun 2025)
Founders & Key People
Shiv RaoSandeep KonamFlorian Metze
Investors
Andreessen Horowitz · Lightspeed Venture Partners · Bessemer Venture Partners · Redpoint · Spark Capital · Kaiser Permanente Ventures · CVS Health Ventures · Khosla Ventures · California Health Care Foundation · NVIDIA NVentures · WndrCo · Emerson Collective · UPMC
Products
- AI ambient clinical documentation
- Epic integration
- Payer-specific note types
- Abridge Contextual Reasoning Engine
- Clinical Decision Support
- Real-time prior authorization
- Revenue cycle intelligence
- Abridge Inside for Inpatient
- Outpatient Orders for Epic
- Nursing documentation solutions
Competitors
Nuance DAX (Microsoft) · Suki · Augmedix · DeepScribe · Nabla · Ambience Healthcare · Heidi Health · Freed
Healthcare AIClinical documentationGenerative AIMedical scribeHealthcare technologyEHR integrationRevenue cycle managementAmbient listeningNatural language processing
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q2. Refreshed quarterly.